Flinton Capital Management’s United Therapeutics UTHR Stock Holding History

Flinton Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$1.07M	Sell	13,384 -10,360	-44%	-$834K	0.03%	308
2019 Q2	$1.85M	Sell	23,744 -11,760	-33%	-$1.1M	0.06%	230
2019 Q1	$4.17M	Sell	35,504 -23,100	-39%	-$2.69M	0.14%	135
2018 Q4	$6.38M	Buy	58,604 +4,116	+8%	+$477K	0.24%	95
2018 Q3	$6.97M	Buy	54,488 +14,280	+36%	+$1.77M	0.22%	104
2018 Q2	$4.55M	Buy	40,208 +8,288	+26%	+$911K	0.15%	131
2018 Q1	$3.59M	Buy	31,920 +23,576	+283%	+$3M	0.12%	153
2017 Q4	$1.24M	Buy	8,344 +3,220	+63%	+$409K	0.04%	257
2017 Q3	$600K	Sell	5,124 -16,380	-76%	-$2.09M	0.02%	370
2017 Q2	$2.79M	Sell	21,504 -7,868	-27%	-$982K	0.1%	164
2017 Q1	$3.98M	Sell	29,372 -12,544	-30%	-$1.9M	0.15%	128
2016 Q4	$6.01M	Buy	+41,916	New	+$5.35M	0.26%	73

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Flinton Capital Management's UTHR Position: Q3 2019 in Review

Flinton Capital Management reduced its United Therapeutics (UTHR) stake by 44% in Q3 2019, selling an estimated $834K and leaving 13,384 shares worth $1.07M. The position accounts for 0.03% of the portfolio, ranked #308.

Flinton Capital Management first reported a position in UTHR in Q4 2016 and has held it in 12 quarters since. The position peaked at $6.97M in Q3 2018. 302 funds tracked by Wall St. Rank hold UTHR as of Q3 2019.

Flinton Capital Management held 13,384 shares of United Therapeutics worth $1.07M as of Q3 2019.
Flinton Capital Management sold 10,360 United Therapeutics shares in Q3 2019, an estimated $834K.
United Therapeutics made up 0.03% of Flinton Capital Management's portfolio in Q3 2019, its #308 holding.
Flinton Capital Management first reported a position in United Therapeutics in Q4 2016 and has held it in 12 quarters since.
Flinton Capital Management's United Therapeutics position peaked at $6.97M in Q3 2018.
302 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.